-
CryoLife's (Kennesaw, Georgia) decellularized replacement heart valve used to replace diseased, damaged, malformed or malfunctioning pulmonary valves in early February received FDA 510(k) clearance. Children who face multiple surgeries for congenital heart defects will likely be the most significant beneficiaries of the new valves, according to the company, by potentially reducing the number of surgeries they must have over a lifetime.
-
Cardiva Medical; ev3; LifeSync; NewCardio; Stereotaxis
-
The most common way to investigate the functions of miRNAs is to inhibit them one at a time.
-
The American Heart Association (AHA; Dallas) recently reported that U.S. deaths from heart disease and stroke dropped about 25% from 1999 to 2005, five years ahead of goals.
-
diaDexus (San Francisco) has received FDA clearance for a new automated version of its PLAC Test.
-
-
Heart drugs aren't all that controversial, but the approval of the heart failure drug BiDil raised some interesting questions. And its future is currently in doubt.
-
Cytori Therapeutics (San Diego) reported receiving its first orders from Europe and Asia for Celution 800 Systems. Eleven Celution 800 Systems and related CT-805 single-use consumables were ordered by Cytori's distributors MBA Grupo, which covers Spain, Italy, and Portugal, and Astrea International, which covers Singapore. Cytori says the first devices are to be delivered this quarter.
-
FORT LAUDERDALE, Florida The field of cardiothoracic surgery is clearly in transition not a new development but one heightened by a variety of pressures, professional, technological, political and economic. This assertion was highlighted in a variety of ways at the organizations annual meeting here in late January.
-
Ablation Frontiers (Carlsbad, California) reported receiving FDA approval to extend U.S. enrollment in its clinical trial for interventional treatment of chronic AF.